News

Number of news items returned: 181 to 200 records of 424

ATIC reports Stellar Investment Portfolio Performance

26 May 2016

(12669 views)

 ATIC reports Stellar Investment Portfolio Performance Australian Trading and Investment Corporation Ltd reports: " Outstanding investment portfolio performance Expanded product/service offer ATIC is holding ...

Benojo - Latest news - May 2016

24 May 2016

(13598 views)

"As Benojo begins to ramp up in the Australian domestic market it attracts a globally recognised CEO, US interest, acquires ...

BlueMount Capital WA Office bolsters portfolio offering in the Food & Beverages Sector

23 May 2016

(12917 views)

BlueMount Capital WA Office bolsters portfolio offering in the Food & Beverages Sector "The Western Australian Office of BlueMount Capital is ...

Opmantek recognised as one of America's most innovative companies in the 2016 American Business Awards

23 May 2016

(12823 views)

OPMANTEK RECOGNISED AS ONE OF AMERICA’S MOST INNOVATIVE COMPANIES IN THE 2016 AMERICAN BUSINESS AWARDSSM " Opmantek has been named as one of America’s most ...

BR Sustainable Investments Australia Recommends Trac Offer

20 May 2016

(13154 views)

" Please read the prospectus documents. ASX code TRC, bookbuild code TRCXBB. We recommend the offer. The levels of CO2 in the atmosphere ...

Paradigm & IODM - Extension of Offer

05 May 2016

(12717 views)

"Paradigm Metals Limited (ASX: PDM) wishes to announce that the Offers under the Prospectus dated 1 April 2016 have been ...

IODM signs strategic alliance agreement with National Credit Insurance

05 May 2016

(13346 views)

"Melbourne, Australia –- May 5, 2016: Paradigm Metals Limited (“Paradigm” or “the Company”) is pleased to announce that IODM has ...

Introductions to Solar, Balustrades, Automated AR Cycle plus news - Funding Strategies Connect April May 2016

29 April 2016

(12541 views)

  Introductions to Solar, Balustrades, Automated AR Cycle plus news - Funding Strategies Connect April/May 2016 Dear Readers, As I am heading off ...

Ocular Robotics: The Company Appoints Turkish Distribution Partner LEO Engineering, and Impressive Display of Ocular Robotics’ Products at Connect Expo 2016

26 April 2016

(13169 views)

"Ocular Robotics Appoints Turkish Distribution Partner LEO Engineering Ocular Robotics is pleased to announce the appointment of Turkish automation technology reseller ...

Opmantek in record period of growth

26 April 2016

(13200 views)

"The Opmantek management team was pleased to report excellent Q1 closing figures during a shareholder update web conference last Thursday. “The ...

IODM Market Update

26 April 2016

(12746 views)

" Paradigm Metals Limited (“Paradigm” or “the Company”) is pleased to provide an IODM Market Summary as provided by the management of IODM. Focus ...

Integrity Compliance Systems' CEO invited to speak at major food safety conferences

22 April 2016

(13169 views)

" ICS provide the only training course in Australia for Vulnerability Assessment and Critical Control Points (VACCP) plan, which is now ...

ATIC: New Revenue Streams

22 April 2016

(13237 views)

"Funds Management services to start in June 2016 Until now ATIC’s core product has been equity research, and resulting buy/sell share ...

23rd Annual AustCham Westpac Australia-China Business Awards Winners Announced

14 April 2016

(13093 views)

"Shanghai: 14th April - The AustCham Westpac Australia-China Business Awards Gala Dinner last night recognised Australian and Chinese businesses in ...

Integrity Compliance Solutions wins US based seafood processing giant Trident Seafood

06 April 2016

(14409 views)

 Integrity Compliance Solutions wins US based seafood processing giant Trident Seafood    "It is an exciting time for Integrity Compliance Systems Limited ...

China Dairy IPO closes following solid demand

05 April 2016

(13429 views)

"China Dairy Corporation Limited (“China Dairy or “the Company”) today announced the successful closure of its ASX IPO following solid ...

BlueMount Capital in Perth has expanded its senior ranks

05 April 2016

(13810 views)

BlueMount Capital in Perth has expanded its senior ranks with the addition of Patrick Kedemos as Managing Partner and James ...

Everything you need to know about Building-integrated photovoltaics

30 March 2016

(12626 views)

"...But while major installations might be few and far between, there are some exciting developments in design and innovation. Leading ...

Ocular Robotics: Ocular Technology Applied to Solve Structural Fatigue Testing Limitations, and March a Busy Time for Exhibition of Ocular Products Around the World

23 March 2016

(13442 views)

"Ocular Technology Applied to Solve Structural Fatigue Testing Limitations One of the most exciting features of the OCR business for the ...

ATIC: Sales Team Growing & Marketing ramping up!

23 March 2016

(14734 views)

"  4 full time sales staff, 2 more commencing 4th April 2016. Lead generation has commenced via online and telemarketing. 1 full time ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625